The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.

UroGen submitted an NDA for UGN-103 in recurrent NMIBC, T-DXd improved PFS in first-line HER2-mutant lung cancer, and more.

The FDA approved camizestrant plus a CDK4/6 inhibitor for hormone receptor–positive, HER2-negative metastatic breast cancer that acquires an ESR1 mutation.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Daraxonrasib produced a 42% overall response rate and 16.0-month median OS in previously treated RAS-mutant NSCLC in a phase 1/2 trial.

Ivonescimab significantly improved OS vs pembrolizumab at a prespecified interim analysis of the HARMONi-2 trial in first-line PD-L1–positive NSCLC.

GLP-1 receptor agonists are generating buzz for their metabolic benefits, as well as for their potential to directly combat breast cancer progression.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in August 2026 spanning tumor types.